Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

In a phase 2 trial, 10-mg bulevirtide plus pegylated interferon alfa-2a was superior to bulevirtide alone with regard to an undetectable HDV RNA level 24 weeks after the end of treatment in patients with chronic hepatitis D.

​   The New England Journal of Medicine: Search Results in Infectious Disease